Related Experiment Videos
P-glycoprotein, multidrug resistance and tumor progression
1Ontario Cancer Institute, Department of Medical Biophysics, University of Toronto, Canada.
Cancer Metastasis Reviews
|June 1, 1994
Summary
P-glycoprotein (Pgp) in tumors correlates with poor chemotherapy response and survival. Pgp may also drive tumor progression and affect tumor stroma, requiring further study.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- P-glycoprotein (Pgp) is a plasma membrane protein identified in multidrug-resistant cells.
- Pgp expression in clinical tumors is linked to poorer treatment outcomes and shorter survival.
- Pgp overexpression can occur at diagnosis or upon relapse from chemotherapy.
Purpose of the Study:
- To investigate the role of P-glycoprotein in tumor progression and its relationship with treatment outcomes.
- To explore the potential impact of Pgp on tumor stroma and its complex regulation during carcinogenesis.
Main Methods:
- The abstract does not specify the methods used.
- Studies of experimental rat liver carcinogenesis were referenced.
Main Results:
- Pgp detection in tumors correlates with poor chemotherapy response and shorter survival.
- Pgp expression increases in late stages of carcinogenesis, suggesting a role in tumor progression.
- Strong Pgp expression in a rat liver carcinoma model is associated with a highly vascular stroma.
Conclusions:
- P-glycoprotein's role in malignancy and tumor progression warrants further investigation.
- Understanding Pgp regulation and substrate spectrum is crucial for comprehending its biologic effects in tumor cells.
- Further research may elucidate molecular mechanisms underlying tumor progression involving Pgp.